CeriBell (NASDAQ:CBLL) outlined its recent progress and 2026 priorities at a JPMorgan MedTech event, emphasizing continued growth in acute-care seizure detection and an expanding roadmap for ...

Roughly 25 percent of dementia patients were prescribed at least one ‘potentially inappropriate’ drug between 2013 and 2021 ...

Researchers are sounding the alarm on dangerous stimulant medications commonly prescribed to dementia patients in the U.S.

Roughly 25 percent of dementia patients were prescribed at least one ‘potentially inappropriate’ drug between 2013 and 2021 ...

CeriBell Inc. CBLL recently announced that the FDA has granted Breakthrough Device Designation for its Large Vessel Occlusion ...

From prayer times to family vigils, everyday realities can alter how delirium presents — and how clinicians should respond.

Ceribell’s LVO Stroke tool is underpinned by the same EEG monitoring technology used in its seizure and delirium monitoring ...

Ceribell announced today that the FDA granted breakthrough device designation for its large vessel occlusion (LVO) stroke ...

The Breakthrough Device Designation for LVO Stroke represents the latest achievement in Ceribell’s continued efforts to extend its point-of-care EEG brain monitoring technology to additional ...

Instagram is rolling out a new tool called Your Algorithm that gives you direct control over the videos that fill your Reels tab. Your interests shift as time moves on. Now your feed can shift with ...

Issued on behalf of VentriPoint Diagnostics Ltd. Dana Friesen, CEO of Summit Sciences, brings over 15 years of experience in financial analysis and ROI optimization within the medical device and ...

CeriBell Inc. CBLL recently announced that the FDA has given 510(k) clearance for its latest delirium monitoring solution, making it the one and only FDA-cleared solution for continuous tracking of ...